Approval for additional analytical validation data and associated updated product labeling.
Device | Ventana PD-L1 (SP263) |
Classification Name | Immunohistochemistry Assay, Antibody, Programmed Death-ligand 1 |
Generic Name | Immunohistochemistry Assay, Antibody, Programmed Death-ligand 1 |
Applicant | Ventana Medical Systems, Inc. |
Date Received | 2018-04-03 |
Decision Date | 2018-06-01 |
PMA | P160046 |
Supplement | S004 |
Product Code | PLS |
Advisory Committee | Pathology |
Supplement Type | Normal 180 Day Track No User Fee |
Supplement Reason | Postapproval Study Protocol - Ode/oir |
Expedited Review | No |
Combination Product | No |
Applicant Address | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. tucson, AZ 85755 |
Supplemental Filings
Supplement Number | Date | Supplement Type |
P160046 | | Original Filing |
S015 |
2022-10-14 |
30-day Notice |
S014 |
2022-07-12 |
30-day Notice |
S013 | | |
S012 |
2022-02-16 |
Special (immediate Track) |
S011 |
2022-01-28 |
135 Review Track For 30-day Notice |
S010 |
2021-06-14 |
Panel Track |
S009 |
2021-02-22 |
Real-time Process |
S008 |
2020-08-26 |
Real-time Process |
S007 |
2020-01-13 |
Real-time Process |
S006 |
2019-08-22 |
Real-time Process |
S005 |
2018-06-18 |
Real-time Process |
S004 |
2018-04-03 |
Normal 180 Day Track No User Fee |
S003 | | |
S002 | | |
S001 |
2017-07-17 |
30-day Notice |
NIH GUDID Devices